Brief: Simulations Plus Receives U.S. FDA Renewal For Dilisym Software Licenses
18/04/2023 13:35
April 18 (Reuters) - Simulations Plus Inc SLP.O :
* SIMULATIONS PLUS RECEIVES U.S. FDA RENEWAL FOR DILISYM
SOFTWARE
LICENSES
* SIMULATIONS PLUS INC - PROVIDES FDA WITH SOFTWARE TOOLS TO
INVESTIGATE DRUG-INDUCED LIVER INJURY IN CLINICAL TRIALS
Source text for Eikon: ID:nBw4Qwpm0a
Further company coverage: SLP.O
Recent news on Simulations Plus
See all newsBrief: Simulations Plus Altaris To Pay $26 Million Termination Fee To Co If Merger Agreement Terminated
NASDAQ RESUMED AT 09:55 AM
Brief: Simulations Plus To Be Acquired By Altaris For Approximately $375 Million
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:55 AM
Simulations Plus Q2 results beat expectations but lowers annual profit forecast on tax rate jump